Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy
BackgroundPeptide receptor radionuclide therapy (PRRT) is a well-established treatment option for neuroendocrine tumors (NET), yet randomized controlled trials have not provided data on its impact on overall survival. The real-world efficacy of PRRT and its association with tumor functionality and g...
Saved in:
| Main Authors: | Annie Mathew, David Kersting, Wolfgang P. Fendler, Johanna Braegelmann, Dagmar Fuhrer, Harald Lahner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1526470/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report
by: Ryosuke Umino, et al.
Published: (2024-02-01) -
Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy
by: Tobias Stemann Lau, et al.
Published: (2025-06-01) -
Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
by: Turgut Bora Cengiz, et al.
Published: (2025-01-01) -
First results and experience with PRRT in South Africa
by: Mariza Vorster, et al.
Published: (2018-04-01) -
Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists
by: Sandip Basu, et al.
Published: (2019-01-01)